Evaluation of HIF-1 inhibitors as anticancer agents

Drug Discovery Today

Volumn 12, Issue 19-20, 2007, Pages 853-859

  Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DIMETHYLAMINOMETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4,4' ISOPROPYLIDENEDIPHENOL; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; BORTEZOMIB; CELECOXIB; CETUXIMAB; ECHINOMYCIN; ERLOTINIB; EVEROLIMUS; FR 901228; GEFITINIB; GELDANAMYCIN; GENISTEIN; HYPOXIA INDUCIBLE FACTOR 1; IBUPROFEN; IMATINIB; LONAFARNIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NSC 644221; POLYAMIDE; PSEUDOLARIC ACID B; PX 478; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

CANCER; CANCER CELL; CANCER CHEMOTHERAPY; ENZYME ACTIVATION; GENE ACTIVITY; GENE OVEREXPRESSION; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; METASTASIS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROGNOSIS; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 35048875691     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.08.006     Document Type: Review

References (141)

1. Vaupel P., and Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26 (2007) 225-339
2. Manalo D.J., et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 (2005) 659-669
3. Chi J.T., et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3 (2006) e47
4. 2 tension. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5510-5514
5. Tian H., et al. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11 (1997) 72-82
6. Elvidge G.P., et al. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1α, HIF-2α, and other pathways. J. Biol. Chem. 281 (2006) 15215-15226
7. 2 sensing. Science 292 (2001) 464-468
8. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
9. Yu F., et al. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9630-9635
10. Salceda S., and Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272 (1997) 22642-22647
11. Maxwell P.H., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
12. Epstein A.C., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
13. Zhong H., et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59 (1999) 5830-5835
14. Talks K.L., et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157 (2000) 411-421
15. Kondo K., et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
16. Maranchie J.K., et al. The contribution of VHL substrate binding and HIF-1α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
17. Ravi R., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14 (2000) 34-44
18. Stoeltzing O., et al. Role of hypoxia-inducible factor 1α in gastric cancer cell growth, angiogenesis, and vessel maturation. J. Natl. Cancer Inst. 96 (2004) 946-956
19. Acker T., et al. Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8 (2005) 131-141
20. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
21. Beasley N.J., et al. Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 62 (2002) 2493-2497
22. Nakanishi K., et al. Expression of hypoxia-inducible factor-1α protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin. Cancer Res. 11 (2005) 2583-2590
23. Bruick R.K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9082-9087
24. Sowter H.M., et al. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61 (2001) 6669-6673
25. Koukourakis M.I., et al. Hypoxia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 61 (2001) 1830-1832
26. Birner P., et al. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7 (2001) 1661-1668
27. Sturm I., et al. Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ. 13 (2006) 619-627
28. Roe J.S., et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell 22 (2006) 395-405
29. Semenza G.L. Development of novel therapeutic strategies that target HIF-1. Expert Opin. Ther. Targets 10 (2006) 267-280
30. Isaacs J.S., et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J. Biol. Chem. 277 (2002) 29936-29944
31. 2-independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol. Cell 25 (2007) 207-217
32. Kelly B.D., et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93 (2003) 1074-1081
33. Gordan J.D., et al. HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11 (2007) 335-347
34. Bacon A.L., and Harris A.L. Hypoxia-inducible factors and hypoxic cell death in tumor physiology. Ann. Med. 36 (2004) 530-539
35. Korkolopoulou P., et al. Hypoxia-inducible factor 1α/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol. Appl. Neurobiol. 30 (2004) 267-278
36. Theodoropoulos V.E., et al. Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumor recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. 95 (2005) 425-431
37. Theodoropoulos V.E., et al. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur. Urol. 46 (2004) 200-208
38. Zagzag D., et al. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88 (2000) 2606-2618
39. Bos R., et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J. Natl. Cancer Inst. 93 (2001) 309-314
40. Giatromanolaki A., et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1α dependent. Clin. Cancer Res. 10 (2004) 7972-7977
41. Schindl M., et al. Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 8 (2002) 1831-1837
42. Bos R., et al. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97 (2003) 1573-1581
43. Vleugel M.M., et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer. J. Clin. Pathol. 58 (2005) 172-177
44. Dales J.P., et al. Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer 116 (2005) 734-739
45. Kronblad A., et al. Hypoxia inducible factor-1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int. J. Cancer 118 (2006) 2609-2616
46. Trastour C., et al. HIF-1α and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int. J. Cancer 120 (2007) 1443-1450
47. Birner P., et al. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60 (2000) 4693-4696
48. Burri P., et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 56 (2003) 494-501
49. Bachtiary B., et al. Overexpression of hypoxia-inducible factor 1α indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin. Cancer Res. 9 (2003) 2234-2240
50. Kuwai T., et al. Expression of hypoxia-inducible factor-1α is associated with tumor vascularization in human colorectal carcinoma. Int. J. Cancer 105 (2003) 176-181
51. Kimura S., et al. Expression of hypoxia-inducible factor (HIF)-1α is associated with vascular endothelial growth factor expression and tumour angiogenesis in human esophageal squamous cell carcinoma. Eur. J. Cancer 40 (2004) 1904-1912
52. Sivridis E., et al. Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95 (2002) 1055-1063
53. Takahashi R., et al. Hypoxia-inducible factor-1α expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol. Rep. 10 (2003) 797-802
54. Koukourakis M.I., et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 1192-1202
55. Fillies T., et al. HIF-1α overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5 (2005) 84
56. Huang G.W., et al. Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J. Gastroenterol. 11 (2005) 1705-1708
57. Volm M., and Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 20 (2000) 1527-1533
58. Li L., et al. Evaluating hypoxia-inducible factor 1α as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res. 65 (2005) 7249-7258
59. Swinson D.E., et al. Hypoxia-inducible factor-1α in non-small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int. J. Cancer 111 (2004) 43-50
60. Giatromanolaki A., et al. Hypoxia-inducible factors 1α and 2α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 13 (2003) 493-501
61. Birner P., et al. Expression of hypoxia-inducible factor-1α in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92 (2001) 165-171
62. Aebersold D.M., et al. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61 (2001) 2911-2916
63. Kitada T., et al. Clinicopathological significance of hypoxia-inducible factor-1α expression in human pancreatic carcinoma. Histopathology 43 (2003) 550-555
64. Shibaji T., et al. Prognostic significance of HIF-1α overexpression in human pancreatic cancer. Anticancer Res. 23 (2003) 4721-4727
65. Nishi H., et al. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol. Cell. Biol. 24 (2004) 6076-6083
66. Yatabe N., et al. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 23 (2004) 3708-3715
67. Kondoh H., et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 65 (2005) 177-185
68. Covello K.L., et al. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20 (2006) 557-570
69. Lofstedt T., et al. Induction of ID2 expression by hypoxia-inducible factor 1: a role in dedifferentiation of hypoxic neuroblastoma cells. J. Biol. Chem. 279 (2004) 39223-39231
70. Koshiji M., et al. HIF-1α induces genetic instability by transcriptionally downregulating MutSα expression. Mol. Cell 17 (2005) 793-803
71. Maxwell P.H., et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 8104-8109
72. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12 (1998) 149-162
73. Seagroves T.N., et al. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol. Cell. Biol. 21 (2001) 3436-3444
74. Kim J.-W., et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3 (2006) 177-185
75. Papandreou I., et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3 (2006) 187-197
76. Zhang H., et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11 (2007) 407-420
77. Feldser D., et al. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res. 59 (1999) 3915-3918
78. De Paulsen N., et al. Role of transforming growth factor-α in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1387-1392
79. Krishnamachary B., et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63 (2003) 1138-1143
80. Pennacchietti S., et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003) 347-361
81. Krishnamachary B., et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 66 (2006) 2725-2731
82. Esteban M.A., et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 66 (2006) 3567-3575
83. Erler J.T., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006) 1222-1226
84. Comerford K.M., et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62 (2002) 3387-3394
85. Krishnamurthy P., et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. 279 (2004) 24218-24225
86. Laughner E., et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21 (2001) 3995-4004
87. Koukourakis M.I., et al. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIF-1α/VEGF pre-treatment status?. Anticancer Res. 23 (2003) 1673-1680
88. Luwor R.B., et al. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1α, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24 (2005) 4433-4441
89. Mayerhofer M., et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100 (2002) 3767-3775
90. 2 is mediated by hypoxia-inducible factor 1. Cancer Res. 63 (2003) 2330-2334
91. Rapisarda A., et al. Schedule-dependent inhibition of hypoxia-inducible factor-1α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 64 (2004) 6845-6848
92. Kaluz S., et al. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1α C-terminal activation domain. Mol. Cell. Biol. 26 (2006) 5895-5907
93. Yeo E.J., et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 107 (2006) 916-923
94. Majumder P.K., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10 (2004) 594-601
95. Thomas G.V., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12 (2006) 122-127
96. Hiraga T., et al. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 67 (2007) 4157-4163
97. Mabjeesh N.J., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
98. Kong D., et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65 (2005) 9047-9055
99. Newcomb E.W., et al. Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1α expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro-oncology 7 (2005) 225-235
100. Chang H., et al. GL331 inhibits HIF-1α expression in a lung cancer model. Biochem. Biophys. Res. Commun. 302 (2003) 95-100
101. Han J.Y., et al. Hypoxia-inducible factor 1α and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J. Natl. Cancer Inst. 97 (2005) 1272-1286
102. Lee Y.M., et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem. Biophys. Res. Commun. 300 (2003) 241-246
103. Qian D.Z., et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α. Cancer Res. 66 (2006) 8814-8821
104. Richard D.E., et al. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274 (1999) 32631-32637
105. Welsh S.J., et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol. Cancer Ther. 2 (2003) 235-243
106. Kung A.L., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-43
107. Welsh S., et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol. Cancer Ther. 3 (2004) 233-244
108. Yeo E.J., et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95 (2003) 516-525
109. Wang G.L., et al. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. 216 (1995) 669-675
110. Osada M., et al. Apigenin suppresses the expression of VEGF, an important factor for angiogenesis in endothelial cells via degradation of HIF-1α protein. FEBS Lett. 575 (2004) 59-63
111. Liao D., et al. Hypoxia-inducible factor 1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 67 (2007) 563-572
112. Creighton-Gutteridge M., et al. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1α protein accumulation by NSC 644221. Clin. Cancer Res. 13 (2007) 1010-1018
113. Lin S., et al. Berberine inhibits HIF-1α expression via enhanced proteolysis. Mol. Pharmacol. 66 (2004) 612-619
114. Li M.H., et al. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1α by promoting proteasome-mediated degradation. Clin. Cancer Res. 10 (2004) 8266-8274
115. Kubo T., et al. Bisphenol A, an environmental endocrine-disrupting chemical, inhibits hypoxic response via degradation of hypoxia-inducible factor 1α (HIF-1α): structural requirement of bisphenol A for degradation of HIF-1α. Biochem. Biophys. Res. Commun. 318 (2004) 1006-1011
116. Hossain C.F., et al. Saururus cernuus lignans - potent small molecule inhibitors of hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. 333 (2005) 1026-1033
117. Mohammed K.A., et al. Laurenditerpenol, a new diterpene from the tropical marine alga Laurencia intricate that potently inhibits HIF-1-mediated hypoxic signaling in breast tumor cells. J. Nat. Prod. 67 (2004) 2002-2007
118. Tan C., et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 65 (2005) 1-8
119. Olenyuk B.Z., et al. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16768-16773
120. Jones D.T., and Harris A.L. Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol. Cancer Ther. 5 (2006) 2193-2202
121. Escuin D., et al. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor 1α accumulation and activity by disrupting microtubule function. Cancer Res. 65 (2005) 9021-9028
122. Peet D., and Linke S. Regulation of HIF: asparaginyl hydroxylation. Novartis Found. Symp. 272 (2006) 37-49
123. Tang N., et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6 (2004) 485-495
124. Cramer T., et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112 (2003) 645-657
125. Abdollahi A., et al. Endostatin's antiangiogenic signaling network. Mol. Cell 13 (2004) 649-663
126. Semenza G.L., et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271 (1996) 32529-32537
127. Liao D., and Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 26 (2007) 281-290
128. Barnhart B.C., and Simon M.C. Metastasis and stem cell pathways. Cancer Metastasis Rev. 26 (2007) 261-271
129. Bindra R.S., et al. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 26 (2007) 249-260
130. Gillies R.J., and Gatenby R.A. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev. 26 (2007) 311-317
131. Kim J.W., et al. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev. 26 (2007) 291-298
132. Swietach P., et al. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26 (2007) 299-310
133. Sullivan R., and Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 26 (2007) 319-331
134. Chan D.A., and Giaccia A.J. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 26 (2007) 333-339
135. Moeller B.J., et al. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 26 (2007) 241-248
136. Fath D.M., et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-α. J. Biol. Chem. 281 (2006) 13612-13619
137. Magnon C., et al. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1α-mediated tumor apoptotic switch. J. Clin. Invest. 117 (2007) 1844-1855
138. Semenza G.L. Baffled by bafilomycin: an anticancer agent that induces hypoxia-inducible factor-1a expression. Mol. Pharmacol. 70 (2006) 1841-1843
139. Solit D.B., and Rosen N. Hsp90: a novel target for cancer therapy. Curr. Top. Med. Chem. 6 (2006) 1205-1214
140. Senan S., and Smit E.F. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 12 (2007) 465-477
141. Gorre M.E., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880